AbbVie reported strong results from a Phase 3 head-to-head trial, showing that atogepant (as QULIPTA®/AQUIPTA®) was superior to topiramate on all primary and secondary measures for the preventive treatment of migraine. The results represent a major benchmark in migraine therapy, sitting the CGRP receptor antagonist in place as a potentially […]
Phase 3 Trial
Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
articipants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks.
